WS #10795

From 500 msgs · 7 key-dev

FDA issues Complete Response Letter for LNTH-2501 due to third-party manufacturing issues; no safety/efficacy concerns; shares trading lower.

Lantheus FDA CRL

FDA issues Complete Response Letter for LNTH-2501 due to third-party manufacturing issues; no safety/efficacy concerns; shares trading lower.

Full world state #10795 →